The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype☆☆☆
Received 8 October 2007; received in revised form 5 March 2008; accepted 11 March 2008. published online 14 July 2008.
Summary
Gene expression studies have identified a basal phenotype of breast cancer; these are hormone receptor and HER2-negative cancers with poor prognosis. High levels of cyclin E and Skp2, and low levels of p27 have previously been individually associated with both basal-like breast cancer and a poor outcome after diagnosis. The goal of this study was to first confirm the prognostic value of these biomolecular markers using a breast cancer tissue microarray. Second, we also test the hypothesis that the combined phenotype of high cyclin E, low p27, and high Skp2 would be a strong predictor of outcome and would be closely associated with the basal phenotype of breast cancer. Our cohort consisted of 438 cases of breast cancer and the median follow-up was 15.4 years. The tissue microarray was constructed from archival tumor blocks and we used commercially available antibodies for biomarker immunostaining. Cyclin E was positive in 46% of cases, p27 was negative in 62%, and Skp2 was positive in 35%. We found cyclin E and Skp2 to be prognostic for breast cancer–specific survival in univariate analyses, but p27 was not prognostic. The strongest predictor of outcome was the combination of cyclin E positive and Skp2 positive (difference in survival of 19% at 10 years, P = .0009). This combination was present in 78 (27%) of 288 cases for which data on both biomarkers were available. This combination was also highly associated with young age at diagnosis, grade 3 tumors, ER-negative status, HER2-negative status, and the basal biomarkers epidermal growth factor receptor and cytokeratin 5/6. However, in a multivariate model including standard clinicopathologic variables, this combination was not found to have independent prognostic significance. In conclusion, the combination of high cyclin E and Skp2 expression predicts for poor prognosis in breast cancer in univariate analysis only, it is associated with high risk features, and it is associated with the basal phenotype.
aDepartment of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
bGenetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada V6J 3Z6
cDepartment of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada V5Z 1M9
dProgram in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada H2W 1S6
Corresponding author. Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 4E6.
☆ This study examines a novel combination of breast cancer immunohistochemical biomarkers on a large tissue microarray with long follow-up. We show that this combination has prognostic value and is closely associated with the basal breast cancer phenotype.
☆☆ This work was supported by a grant from the Canadian Breast Cancer Research Alliance to WDF and TON. The Genetic Pathology Evaluation Centre is supported by an unrestricted educational grant from Sanofi-Aventis.